Companies: 10,795·Total market cap: $144.5T
Appili Therapeutics Inc.

Appili Therapeutics Inc.

APLIFOTCHealthcare● Active
$0.01
+$0.00(+18.75%)
Market Cap$1585322
P/E Ratio
52W High$0.031
52W Low$0.009

Appili Therapeutics Inc. (APLIF) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

aplif · pe ratio · data through Mar 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Appili Therapeutics Inc. (APLIF) measures how much investors pay for each dollar of the company's trailing earnings. APLIF's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.02.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-03-31

Forward P/E
N/A
FY2026 est. EPS $-0.05
Based on 1 analyst
EPS (TTM)
-$0.02
TTM · diluted EPS
PEG Ratio
-0.05
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Appili Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-15

PE Ratio History

2017 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Appili Therapeutics Inc.
Appili Therapeutics Inc.You
APLIF
$2MN/A-$0.02
America Great Health
America Great Health
AAGH
$4MN/A-$0.00
Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc.
ADXS
$26MN/A-$7.99
Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc.
AGNPF
$2MN/A-$0.58
Health Sciences Group, Inc.
Health Sciences Group, Inc.
HESG
$2MN/A-$0.03
Universal Ibogaine Inc.
Universal Ibogaine Inc.
IBOGF
$10MN/A-$0.06
Imagion Biosystems Limited
Imagion Biosystems Limited
IBXXF
$7MN/A-$0.02

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 9 of 9 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-03-31Latest
FY2025
$-0.02
2024-03-31
FY2024
$-0.03
2023-03-31
FY2023
$-0.08
2022-03-31
FY2022
$-0.38
2021-03-31
FY2021
$-0.24
2020-03-31
FY2020
$-0.13
2019-03-31
FY2019
$-0.14
2018-03-31
FY2018
$-0.12
2017-03-31
FY2017
$-0.06

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Appili Therapeutics Inc. (APLIF) measures how much investors pay for each dollar of the company's trailing earnings. APLIF's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.02.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.01 ÷ -$0.02 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

APLIF pe ratio · 6 questions

APLIF's current PE ratio is N/A as of 2026-06-15, based on a stock price of $0.01 and TTM EPS of -$0.02. Data sourced from Financial Modeling Prep via APLIF's SEC 10-K and 10-Q filings.

APLIF PE ratioWhat is APLIF PE ratioCurrent PE ratio of APLIFAPLIF PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Appili Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15